Abstract
Merck & Co. has entered an exclusive licensing agreement with Taiho Pharmaceutical and Astex Pharmaceuticals for small-molecule cancer drugs that inhibit KRAS. Merck will pay the companies $50 million up front and up to $2.5 billion more depending on drug development and sales milestones. KRAS, one of the frequently mutated genes in cancer, has proved a challenging target for drug development. Taiho and Astex are both part of Japan’s Otsuka Pharmaceutical.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
